107 related articles for article (PubMed ID: 23368942)
1. The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?
Giuliani J; Marzola M
Cutan Ocul Toxicol; 2013 Sep; 32(3):248-51. PubMed ID: 23368942
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Kiyohara Y; Yamazaki N; Kishi A
J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
[TBL] [Abstract][Full Text] [Related]
3. Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?
Giuliani J; Marzola M
Arch Dermatol Res; 2013 Sep; 305(7):653-8. PubMed ID: 23536039
[TBL] [Abstract][Full Text] [Related]
4. The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospecive economic assessment from a single-center experience.
Giuliani J; Indelli M; Marzola M; Raisi E; Frassoldati A
Tumori; 2012; 98(4):408-12. PubMed ID: 23052154
[TBL] [Abstract][Full Text] [Related]
5. Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study.
Acharyya S; Sau S; Dasgupta P; Chakraborty A; Gangopadhyay S
J Indian Med Assoc; 2012 Jul; 110(7):474-6, 493. PubMed ID: 23520673
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic effect of erlotinib in elderly patients with advanced non-small cell lung cancer].
Sun C; Zhang X; Chen Y
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1839-40, 1 p following 1840. PubMed ID: 23268424
[TBL] [Abstract][Full Text] [Related]
7. Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash.
Takashima N; Kimura T; Watanabe N; Umemura T; Katsuno S; Arakawa K; Fukatsu M; Nakamura N; Nishiyama O; Kataoka K; Kondoh Y; Taniguchi H
Onkologie; 2012; 35(12):747-52. PubMed ID: 23207620
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
[TBL] [Abstract][Full Text] [Related]
10. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
11. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
Carlson JJ; Wong WB; Veenstra DL; Reyes C
J Med Econ; 2011; 14(2):159-66. PubMed ID: 21288059
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib].
Böker B; Lüders H; Grohé C
Pneumologie; 2012 Feb; 66(2):89-95. PubMed ID: 22337328
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
[TBL] [Abstract][Full Text] [Related]
14. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
Zhou S; Ren S; Yan L; Zhang L; Tang L; Zhang J; Zhou C
Respirology; 2009 Jul; 14(5):709-15. PubMed ID: 19659649
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
Lind JS; Lagerwaard FJ; Smit EF; Senan S
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1391-6. PubMed ID: 19289264
[TBL] [Abstract][Full Text] [Related]
18. Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients.
Yamazaki N; Kiyohara Y; Kudoh S; Seki A; Fukuoka M
Int J Clin Oncol; 2016 Apr; 21(2):248-253. PubMed ID: 26499382
[TBL] [Abstract][Full Text] [Related]
19. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Spigel DR; Hainsworth JD; Burkett ER; Burris HA; Yardley DA; Thomas M; Jones SF; Dickson NR; Scullin DC; Bradof JE; Rubinsak JR; Brierre JE; Greco FA
Clin Lung Cancer; 2005 Sep; 7(2):127-32. PubMed ID: 16179100
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
Cromwell I; van der Hoek K; Malfair Taylor SC; Melosky B; Peacock S
Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]